I5
I5X.F Precigen Inc
- Market cap
- EUR 1.49B
- P/E
- 46.2x
- P/B
- 19.21x
- ROE
- 76.2%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is I5X.F undervalued?
Graham numberThe Graham number of Precigen Inc cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Precigen Inc fundamental analysis
No fundamental analysis for Precigen Inc yet.
Precigen Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Precigen Inc
Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases. The company offers therapeutic platforms consisting of AdenoVerse platform, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and UltraCAR-T to provide chimeric anti…
Full company profilePrecigen Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Precigen Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 191M | 231M | 161M | 90.7M | 103M | 104M | 26.9M | 6.23M | 3.93M | 9.68M | 203M |
| Gross Profit | 129M | 168M | 97.3M | 29.3M | 47.7M | 45.5M | 20.6M | 106K | -342K | 4.86M | 187M |
| Operating Income | -125M | -121M | -445M | -173M | -85.7M | -78.8M | -74.6M | -88.9M | -94.7M | -107M | 73.7M |
| EBITDA | - | -97.9M | -495M | -166M | -67.9M | -64.3M | -73.2M | -89.2M | -123M | -244M | 80.4M |
| Net Income | -187M | -117M | -509M | -322M | -171M | -92.2M | 28.3M | -95.9M | -126M | -251M | 63.9M |
| EPS | - | -0.96 | -3.18 | -1.97 | -0.91 | -0.45 | 0.14 | -0.39 | -0.43 | -0.71 | 0.18 |
| Balance Sheet | |||||||||||
| Total Assets | 949M | 847M | 716M | 456M | 315M | 360M | 216M | 151M | 145M | 156M | 212M |
| Total Liabilities | 380M | 300M | 337M | 384M | 247M | 253M | 89.7M | 32.5M | 107M | 135M | 128M |
| Shareholders' Equity | 560M | 534M | 363M | 71.7M | 67.2M | 107M | 126M | 118M | 38.5M | 20.9M | 83.8M |
| Cash & Short-term Investments | 62.6M | 68.1M | 103M | 65.8M | 51.8M | 42.9M | 4.86M | 7.58M | 29.5M | 30.2M | 15.0M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -49.0M | -104M | -124M | -136M | -77.0M | -55.8M | -65.0M | -66.9M | -68.2M | -87.8M | -66.3M |
| Capital Expenditure | 31.6M | 60.9M | 41.6M | 37.9M | 7.53M | 7.25M | 4.92M | 1.54M | 8.58M | 2.00M | 1.45M |
| Free Cash Flow | - | -151M | -166M | -174M | -84.5M | -63.0M | -70.0M | -68.5M | -76.8M | -89.8M | -67.8M |
| Ratios | |||||||||||
| ROE | -33.3% | -21.9% | -140.4% | -449.5% | -253.8% | -85.9% | 22.4% | -80.9% | -327.8% | -1,198.6% | 76.2% |
| ROA | -19.7% | -13.8% | -71.1% | -70.7% | -54.2% | -25.6% | 13.1% | -63.5% | -86.9% | -161.2% | 30.1% |
| Net Profit Margin | -97.7% | -50.7% | -317.2% | -355.3% | -165.3% | -88.7% | 105.2% | -1,540.6% | -3,216.2% | -2,588.2% | 31.4% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Precigen Inc dividends
Precigen Inc has not paid dividends in the last 9 fiscal years.
Who owns Precigen Inc
- Insiders 12.62%
- Institutions 73.58%
- Public & others 13.80%
- Shares outstanding 359M
- Free float 195M
Precigen Inc company profile
- Company name
- Precigen Inc
- Ticker
- I5X.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 160
- Fiscal year end
- December
- Address
- 20374 Seneca Meadows Parkway, Germantown, MD, United States, 20876
- Phone
- 301 556 9900
- Website
- precigen.com
About Precigen Inc
Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases. The company offers therapeutic platforms consisting of AdenoVerse platform, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1/1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV+ solid tumors; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis. Further, it provides UltraPorator, a proprietary electroporation device. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.
Precigen Inc management
10- Mr. Randal J. Kirk J.D.Executive Chairman · born 1953
- Dr. Helen Sabzevari MPH, Ph.D.President, CEO & Director · born 1962
- Mr. Harry Thomasian Jr.Chief Financial Officer · born 1962
- Mr. Rutul R. ShahChief Operating Officer · born 1981
- Mr. Donald P. Lehr J.D., Ph.D.Chief Legal Officer & Corporate Secretary · born 1975
- Mr. Phil TennantChief Commercial Officer · born 1970
- Mr. Steven M. HarasymVP & Head of Investor Relations
- Dr. Douglas E. Brough Ph.D.Senior VP & Head of Research · born 1955
- Dr. Bryan T. Butman Ph.D.Senior VP & Head of CMC · born 1953
- Dr. Amy R. Lankford Ph.D.Senior VP & Global Head of Regulatory Affairs